home / stock / rhhbf / rhhbf articles
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OT...
Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic too...
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY) for two undisclosed early-sta...
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-ex...
Roche Holdings AG (OTC: RHHBY) announced that the Phase 3 ALINA study evaluating Alecensa (alectinib), compared with platinum-based chemothera...
The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to the National Health Service (NHS) to im...
News, Short Squeeze, Breakout and More Instantly...
Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare Canada NewsWire The report shows digital health technologies demonstrate value, yet integrating th...
Development in Alzheimer's disease diagnosis in Canada: New tests help patients and caregivers make timely decisions Canada NewsWire Roche's Cerebrospinal Fluid (CSF) assays address unmet needs in the detection of amyloid pathology by offering greater accessibility and support...